| Previous Close | 0.4520 |
| Open | 0.4650 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.4650 - 0.4650 |
| 52 Week Range | 0.3700 - 1.3700 |
| Volume | 370 |
| Avg. Volume | 127 |
| Market Cap | 12.244M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0870 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
TORONTO, April 23, 2019 /CNW/ - Canntab Therapeutics Limited (CSE:PILL.CN - News) (OTCQB:CTABF - News) (FRA:TBF1.F - News) (the "Company" or "Canntab") is pleased to announce that by virtue of FSD Pharma Inc. ("FSD"), with whom Canntab has entered into a collaboration and profit sharing agreement, being granted a "sale for medical purposes" licence by Health Canada pursuant to the Cannabis Act and Cannabis Regulations (the "FSD Licence"), Canntab is close to being in a position to sell its products and generate revenue. The FSD Licence allows Canntab to produce samples of capsules containing CBD and/or THC, which, if approved by Health Canada, will enable Canntab to launch production and sales out of its manufacturing facility located in Room 6 of FSD's Health Canada approved facility in Cobourg, Ontario.
Canntab Therapeutics Limited (CSE:PILL) (the “Company” or “Canntab”) is pleased to announce that, effective March 21, 2019, it has engaged Relations Publiques Paradox Inc. (“Paradox”) to provide investor relations services to the Company. Paradox is a Montreal based investor relations consultancy firm that has been in business for 20 years, and is led by entrepreneur, Jean-Francois Meilleur. Paradox has represented a number of public companies through its extensive network and experience in the capital markets.
Canntab Therapeutics Limited (CSE: PILL, OTCQB: CTABF, FSE: TBF1) (“Canntab” or the “Company”) is pleased to announce that it has entered into a supply and loan agreement (the “Agreement”) with FSD Pharma Inc. (“FSD”) and World Class Extractions Inc. (“World Class”) (collectively, the “Purchasers”) to purchase hemp flower from Thomas Elcome (the “Supplier”). Pursuant to the Agreement, the Supplier grants the Purchasers the right and option to purchase up to CAD $5.0 million of the Supplier’s hemp crop for a period of 5 years commencing in 2019 at a purchase price of CAD $100.0 per kg per 1% of CBD extracted from the flower.
Moving into FSD Pharma and FSD Processing LicenseMackie Research ExtensionDirector Estate Planning InitiativeOTCQB under symbol CTABF TORONTO, Feb. 19, 2019 -- Canntab.
Canntab Therapeutics Limited (CSE: PILL, FSE: TBF1) (“Canntab”), a leader in the development of precision oral dose cannabis tablets and capsules, announced today that it has entered into a supply agreement (the “Agreement”) with FSD Pharma Inc. (“FSD Pharma”) and World Class Extractions Inc. (“World Class”) (the “Purchasers”) to purchase hemp flower from Thomas Elcome (the “Supplier”). Pursuant to the agreement, the Purchasers have agreed to buy approximately 1,000 kg of the Supplier’s 2018 hemp crop at a purchase price of $100.00 per kg per 1% of CBD extracted from the flower.
SEATTLE, Jan. 17, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing FSD Pharma Inc’s. (CSE:HUGE) (FSDDF) (0K9.F) & Canntab Therapeutics Ltd’s. (CSE:PILL) (TBF1.F) performance in 2018. The cannabis industry experienced significant growth last year, particularly in Canada following the legalization of adult-use cannabis on a federal level. The upcoming legalization of edible products across Canada could open the door to further growth in 2019 and beyond.
SEATTLE, Dec. 21, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing Canntab Therapeutics Ltd. (CSE:PILL) (TBF1.F). The company is an emerging leader in solid oral dosage cannabis formulations, which are designed to make cannabinoid dosing more accurate and reliable. With 13 patents pending in the United States and Canada, the company is developing instant release, extended release, flash melt, and bi-layer tablets available in 2.5mg, 5mg, and 10mg formulations to ease these concerns.
SEATTLE, Dec. 13, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing Canntab Therapeutics Ltd. (CSE:PILL) (TBF1.F), The company recently announced a partnership with world-renowned orthopaedic surgeon, Dr. Don Garbuz, MD, to conduct a clinical trial to analyze the efficacy of cannabis as a replacement for opioids in postoperative care. The opioid industry is expected to generate nearly $20 billion in annual revenue by 2020, but the addictive nature of the drug has doctors and patients increasingly concerned. With the legalization of cannabis across Canada and many U.S. states, there’s an opportunity to replace dangerous opioids with efficacious cannabinoids to treat chronic and acute pain.
Partnership formed with Dr. Don Garbuz, an award winning orthopaedic surgeon and medical researcher, credited with over 120 peer reviewed publications. The parties will seek to conduct a clinical study with orthopaedic patients, using Canntab’s sustained release tablets. The study will also seek to show the efficacy of Canntab’s cannabis products for pain management and improvements in patient overall health outcomes.
SEATTLE, Nov. 29, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing a key problem facing the medical cannabis industry: dosing and consistency. Unlike pharmaceuticals, medical cannabis is typically prescribed in a smokable form that can produce inconsistent effects between patients. Many pharmaceuticals also offer extended release and features that can make the medicine more efficacious.
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE U.S. TORONTO, Nov. 14, 2018 -- Canntab Therapeutics Limited (CSE: PILL, FSE: TBF1) (“Canntab” or.
Canntab Therapeutics Limited (CSE: PILL, FSE: TBF1) (“Canntab” or the “Company”) is a company with a clear vision of becoming the leader in solid oral dosage formulation of cannabis. Their unique products offer advantages to the medical community, patients, adult use consumers and governments. Canntab is pleased to provide this corporate update to its shareholders. A strong intellectual property portfolio with 13 patents pending in the United States and Canada pertaining to the formulation of tablets including instant release, extended release, flash melt and bi-layered. An application to become a Licensed Producer (Non Grower) under the Access to Cannabis for Medical Purposes Regulations and has confirmation from Health Canada that its application had been received.
Canntab Therapeutics Limited (CSE: PILL, FSE: TBF1) (“Canntab” or the “Company”) today announced the signing of a non-binding Letter of Intent (the “LOI”) with Labsco Promedic SA de CV of Monterrey, Mexico (“Labsco”) for the establishment of a joint venture relationship for the sales & distribution of Canntab products in Mexico (the “Territory”) on an exclusive basis. Following the LOI, the parties will work together to establish and complete a formal joint venture relationship for an initial period of five years.
Toronto, Ontario--(Newsfile Corp. - May 25, 2018) - Canntab Therapeutics Limited (CSE: PILL) (formerly Telferscot Resources Inc.) ("Canntab" or the "Company") is pleased to announce that it continues to expand its extensive intellectual property portfolio through the recent filing of 2 additional Canadian patent applications. Canntab's portfolio now includes 13 patent applications in Canada, the United States and internationally. These filings build on Canntab's growing intellectual property portfolio, which already included patent applications and ...